4.3 Article

Evaluation of anticancer activity of celastrol liposomes in prostate cancer cells

期刊

JOURNAL OF MICROENCAPSULATION
卷 31, 期 5, 页码 501-507

出版社

TAYLOR & FRANCIS LTD
DOI: 10.3109/02652048.2013.879932

关键词

Celastrol; liposomes; prostate cancer

资金

  1. Methodist Hospital Research Institute
  2. Ernest Cockrell Jr. Distinguished Endowed Chair
  3. US Department of Defense [W81XWH-09-1-0212]
  4. National Institute of Health [U54CA143837, U54CA151668]
  5. Nylands nation Finland
  6. Department of Defense [W81XWH-12-1-0414]
  7. State of Texas CPRIT grant [RP121071]
  8. NATIONAL CANCER INSTITUTE [U54CA143837, U54CA151668] Funding Source: NIH RePORTER

向作者/读者索取更多资源

Context: Celastrol, a natural compound derived from the herb Tripterygium wilfordii, is known to have anticancer activity, but is not soluble in water. Objective: Formation of celastrol liposomes, to avoid the use of toxic solubilising agents. Materials and methods: Two different formulations of PEGylated celastrol liposomes were fabricated. Liposomal characteristics and serum stability were determined using dynamic light scattering. Drug entrapment efficacy and drug release were measured spectrophotometrically. Cellular internalisation and anticancer activity was measured in prostate cancer cells. Results: Liposomal celastrol displayed efficient serum stability, cellular internalisation and anticancer activity, comparable to that of the free drug reconstituted in dimethyl sulfoxide. Discussion and conclusion: Liposomal celastrol can decrease the viability of prostate cancer cells, while eliminating the need for toxic solubilising agents.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据